SB202190
To Order Contact us: lieven@wlsolutions.be
SB202190 |
||
SIH-473-5MG | 5 mg | EUR 76.8 |
SB202190 (FHPI) |
||
A1632-100 | 100 mg | EUR 80 |
Description: MAPK Signaling|p38 |
SB202190 (FHPI) |
||
A1632-5.1 | 10 mM (in 1mL DMSO) | EUR 44 |
Description: MAPK Signaling|p38 |
SB202190 (FHPI) |
||
MBS575414-100mg | 100mg | EUR 175 |
SB202190 (FHPI) |
||
MBS575414-10mg | 10mg | EUR 135 |
SB202190 (FHPI) |
||
MBS575414-200mg | 200mg | EUR 225 |
SB202190 (FHPI) |
||
MBS575414-25mg | 25mg | EUR 140 |
SB202190 (FHPI) |
||
MBS575414-50mg | 50mg | EUR 145 |
SB202190 (FHPI, 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole) |
||
MBS6023840-1mg | 1(mg | EUR 345 |
SB202190 (FHPI, 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole) |
||
MBS6023840-25mg | 25mg | EUR 400 |
SB202190 (FHPI, 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole) |
||
MBS6023840-5mg | 5(mg | EUR 475 |
SB202190 (FHPI, 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole) |
||
MBS6023840-5x5mg | 5x5mg | EUR 1990 |
SB-7720770 2HCl |
||
562446 | 5.0mg | EUR 400 |
SB4315242, Free Base [CAS# 301836-41-9] |
||
S-7800 | 5 mg | EUR 48 |
SB-222200 |
||
A3795-10 | 10 mg | EUR 96 |
Description: GPCR/G protein|NK3 Receptor |
SB-222200 |
||
A3795-5.1 | 10 mM (in 1mL DMSO) | EUR 104 |
Description: GPCR/G protein|NK3 Receptor |
SB-222200 |
||
A3795-50 | 50 mg | EUR 412.8 |
Description: GPCR/G protein|NK3 Receptor |
SB-674042 |
||
A3800-10 | 10 mg | EUR 203.2 |
Description: GPCR/G protein|OX Receptor |
SB-674042 |
||
A3800-25 | 25 mg | EUR 717.6 |
Description: SB-674042 is a specific, high-affinity OX1 selective antagonist. |
SB-674042 |
||
A3800-5 | 5 mg | EUR 121.6 |
Description: GPCR/G protein|OX Receptor |
SB-204990 |
||
551029 | 1.0mg | EUR 225 |
SB203850 |
||
555153 | 10.0mg | EUR 265 |
SB-297006 |
||
555605 | 100.0mg | EUR 450 |
SB-242235 |
||
510235 | 10.0mg | EUR 285 |
SB-202190 |
||
510242 | 50.0mg | EUR 300 |
SB269652 |
||
522353 | 5.0mg | EUR 255 |